Principal Financial Group Inc Exelixis, Inc. Transaction History

Principal Financial Group Inc

$1.66 Trillion
Q3 2024

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	SELL	$21.96 - $27.6 $6.74 Million - $8.47 Million	-306,948 Reduced 31.56%	665,742 $17.3 Million
Q2 2024 Jul 29, 2024	SELL	$20.34 - $23.73 $3.53 Million - $4.12 Million	-173,467 Reduced 15.13%	972,690 $21.9 Million
Q1 2024 Apr 29, 2024	SELL	$20.17 - $23.93 $116,622 - $138,363	-5,782 Reduced 0.5%	1,146,157 $27.2 Million
Q4 2023 Feb 07, 2024	SELL	$19.25 - $24.13 $665,530 - $834,246	-34,573 Reduced 2.91%	1,151,939 $27.6 Million
Q3 2023 Nov 02, 2023	SELL	$19.04 - $22.74 $910,302 - $1.09 Million	-47,810 Reduced 3.87%	1,186,512 $25.9 Million
Q2 2023 Aug 07, 2023	SELL	$18.17 - $20.48 $904,030 - $1.02 Million	-49,754 Reduced 3.87%	1,234,322 $23.6 Million
Q1 2023 May 09, 2023	BUY	$16.3 - $19.41 $177,001 - $210,773	10,859 Added 0.85%	1,284,076 $24.9 Million
Q4 2022 Feb 09, 2023	BUY	$14.96 - $17.39 $260,184 - $302,446	17,392 Added 1.38%	1,273,217 $20.4 Million
Q3 2022 Nov 09, 2022	SELL	$15.68 - $22.27 $251,507 - $357,210	-16,040 Reduced 1.26%	1,255,825 $19.7 Million
Q2 2022 Aug 10, 2022	BUY	$17.44 - $23.16 $3.42 Million - $4.54 Million	196,160 Added 18.24%	1,271,865 $26.5 Million
Q1 2022 May 09, 2022	SELL	$17.03 - $22.67 $169,295 - $225,362	-9,941 Reduced 0.92%	1,075,705 $24.4 Million
Q4 2021 Feb 09, 2022	SELL	$15.84 - $21.88 $151,652 - $209,479	-9,574 Reduced 0.87%	1,085,646 $19.8 Million
Q3 2021 Nov 09, 2021	SELL	$16.3 - $21.14 $32,811 - $42,554	-2,013 Reduced 0.18%	1,095,220 $23.2 Million
Q2 2021 Aug 10, 2021	BUY	$17.95 - $25.56 $361,333 - $514,522	20,130 Added 1.87%	1,097,233 $20 Million
Q1 2021 May 10, 2021	BUY	$20.53 - $25.22 $3.11 Million - $3.83 Million	151,703 Added 16.39%	1,077,103 $24.3 Million
Q4 2020 Feb 08, 2021	BUY	$18.39 - $24.8 $49,174 - $66,315	2,674 Added 0.29%	925,400 $18.6 Million
Q3 2020 Nov 06, 2020	SELL	$20.67 - $26.94 $555,216 - $723,635	-26,861 Reduced 2.83%	922,726 $22.6 Million
Q2 2020 Aug 05, 2020	BUY	$16.46 - $27.42 $309,711 - $515,934	18,816 Added 2.02%	949,587 $22.5 Million
Q1 2020 May 12, 2020	SELL	$14.46 - $21.8 $5.61 Million - $8.46 Million	-387,956 Reduced 29.42%	930,771 $16 Million
Q4 2019 Feb 05, 2020	BUY	$15.15 - $18.89 $41,632 - $51,909	2,748 Added 0.21%	1,318,727 $23.2 Million
Q3 2019 Nov 13, 2019	SELL	$17.68 - $22.65 $350,629 - $449,194	-19,832 Reduced 1.48%	1,315,979 $23.3 Million
Q2 2019 Aug 12, 2019	BUY	$18.93 - $24.75 $74,584 - $97,515	3,940 Added 0.3%	1,335,811 $28.5 Million
Q1 2019 May 10, 2019	BUY	$19.6 - $24.76 $279,594 - $353,201	14,265 Added 1.08%	1,331,871 $31.7 Million
Q4 2018 Feb 14, 2019	SELL	$13.65 - $21.8 $299,521 - $478,357	-21,943 Reduced 1.64%	1,317,606 $25.9 Million
Q3 2018 Nov 14, 2018	BUY	$15.87 - $22.4 $1.38 Million - $1.95 Million	87,093 Added 6.95%	1,339,549 $23.7 Million
Q2 2018 Aug 13, 2018	BUY	$18.56 - $22.45 $21.6 Million - $26.1 Million	1,161,450 Added 1276.23%	1,252,456 $0
Q1 2018 May 14, 2018	BUY	$22.15 - $31.89 $98,456 - $141,751	4,445 Added 5.14%	91,006 $2.02 Million
Q4 2017 Feb 13, 2018	BUY	$24.23 - $30.93 $919,916 - $1.17 Million	37,966 Added 78.13%	86,561 $2.63 Million
Q3 2017 Nov 02, 2017	BUY	$23.35 - $29.24 $1.13 Million - $1.42 Million	48,595	48,595 $1.18 Million

Others Institutions Holding EXEL

# of Institutions

502

Shares Held

243M

Call Options Held

2.54M

Put Options Held

2.29M

Black Rock Inc. New York, NY

33.5M
Shares

$1.13 Billion
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

29.3M
Shares

$988 Million
0.01% of portfolio
Farallon Capital Management LLC San Francisco, CA

25.4M
Shares

$856 Million
3.31% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

15.4M
Shares

$518 Million
0.63% of portfolio
State Street Corp Boston, MA

11.4M
Shares

$386 Million
0.01% of portfolio

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.8B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account